{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:02:34Z","timestamp":1787022154914,"version":"build-2736575974"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003653","name":"Korea National Institute of Health","doi-asserted-by":"crossref","award":["2022E200100 & 2020ER520502"],"award-info":[{"award-number":["2022E200100 & 2020ER520502"]}],"id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Chonnam National University Hospital Biomedical Research Institute.","award":["BCRI24033"],"award-info":[{"award-number":["BCRI24033"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pyrazinamide (PZA) usage has been associated with adverse drug reactions, prompting its avoidance in treating elderly tuberculosis (TB) patients. This study aims to examine whether the administration of PZA is associated with poor outcomes during TB treatment among elderly individuals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis was undertaken on data collected from a prospective cohort conducted between July 2019 and June 2023, which involved tuberculosis patients from 18 institutions across the Republic of Korea. The study aimed to assess the impact of PZA on the incidence of serious adverse events (SAEs), medication interruptions, and becoming loss to follow-up (LTFU) during standard short courses of TB treatment in elderly (\u226565 years old) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>PZA was administered to 356 of 390 elderly patients (91.3%), and 98 of the 390 (25.1%) experienced SAEs. Treatment success was significantly lower in patients not treated with PZA compared to those who received PZA (64.7% vs 89.9%, p &lt; 0.001). The incidence of SAEs, medication interruption, or LTFU was higher in patients not given PZA compared those who received PZA (52.9% vs. 27.2%, p = 0.002). A multivariate logistic regression analysis, factoring in covariates such as age, comorbidities, and baseline laboratory data, revealed that PZA was not a risk factor for SAEs, medication interruption, or LTFU in TB treatment (odds ratio [OR] 0.457, 95% confidence interval [CI] 0.201\u20131.041).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Treating elderly TB patients with PZA did not increase the incidence of SAEs, medication interruptions, or LTFU during the standard short course of TB treatment. Therefore, considering its potential advantages, incorporating PZA into the treatment regimen for elderly TB patients may be advisable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0309902","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T13:25:17Z","timestamp":1727357117000},"page":"e0309902","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Impact of pyrazinamide usage on serious adverse events in elderly tuberculosis patients: A multicenter cohort study"],"prefix":"10.1371","volume":"19","author":[{"given":"Joon Young","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Ok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Sang","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eung Gu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Soo","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Youn","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Haak","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seunghoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun-Hyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeonhee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6091-518X","authenticated-orcid":true,"given":"Jinsoo","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5121-4488","authenticated-orcid":true,"given":"Yong-Soo","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,9,26]]},"reference":[{"issue":"1","key":"pone.0309902.ref001","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1016\/S2666-5247(22)00359-7","article-title":"WHO\u2019s Global Tuberculosis Report 2022","volume":"4","author":"S Bagcchi","year":"2023","journal-title":"Lancet Microbe"},{"key":"pone.0309902.ref002","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12879-016-1451-0","article-title":"Does tuberculosis threaten our ageing populations?","volume":"16","author":"R Byng-Maddick","year":"2016","journal-title":"BMC Infect Dis."},{"issue":"5","key":"pone.0309902.ref003","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1440-1843.2010.01784.x","article-title":"Tuberculosis at extremes of age","volume":"15","author":"HS Schaaf","year":"2010","journal-title":"Respirology"},{"issue":"11","key":"pone.0309902.ref004","doi-asserted-by":"crossref","first-page":"869","DOI":"10.5588\/ijtld.23.0145","article-title":"TB in ageing populations: lessons from Japan and Korea","volume":"27","author":"MM Cho","year":"2023","journal-title":"Int J Tuberc Lung Dis"},{"issue":"7","key":"pone.0309902.ref005","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis","volume":"63","author":"P Nahid","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"11","key":"pone.0309902.ref006","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1164\/rccm.200206-626OC","article-title":"Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis","volume":"167","author":"D Yee","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"pone.0309902.ref007","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1093\/cid\/ciz306","article-title":"Tuberculosis in Older Adults: Seattle and King County, Washington","volume":"70","author":"K Gardner Toren","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"7","key":"pone.0309902.ref008","doi-asserted-by":"crossref","first-page":"871","DOI":"10.5588\/ijtld.10.0352","article-title":"A systematic review of risk factors for death in adults during and after tuberculosis treatment","volume":"15","author":"CJ Waitt","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"issue":"4","key":"pone.0309902.ref009","doi-asserted-by":"crossref","first-page":"486","DOI":"10.5588\/ijtld.12.0133","article-title":"Non-adherence and drug-related interruptions are risk factors for delays in completion of treatment for tuberculosis","volume":"17","author":"AC Pettit","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"pone.0309902.ref010","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s40266-020-00811-9","article-title":"Safety of Pyrazinamide for the Treatment of Tuberculosis in Older Patients Over 75 Years of Age: A Retrospective Monocentric Cohort Study.","volume":"38","author":"S Rousset","year":"2021","journal-title":"Drugs Aging."},{"issue":"9","key":"pone.0309902.ref011","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s40266-021-00880-4","article-title":"Pulmonary Tuberculosis in Older Adults: Increased Mortality Related to Tuberculosis Within Two Months of Treatment Initiation.","volume":"38","author":"I Hase","year":"2021","journal-title":"Drugs Aging"},{"issue":"7","key":"pone.0309902.ref012","doi-asserted-by":"crossref","first-page":"e0236109","DOI":"10.1371\/journal.pone.0236109","article-title":"The high incidence of severe adverse events due to pyrazinamide in elderly patients with tuberculosis","volume":"15","author":"BS Kwon","year":"2020","journal-title":"PLoS One"},{"issue":"8","key":"pone.0309902.ref013","article-title":"Active Pulmonary Tuberculosis in Elderly Patients: A 2016\u20132019 Retrospective Analysis from an Italian Referral Hospital.","volume":"9","author":"F Di Gennaro","year":"2020","journal-title":"Antibiotics (Basel)."},{"key":"pone.0309902.ref014","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2147\/CIA.S95411","article-title":"The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide.","volume":"11","author":"HS Lin","year":"2016","journal-title":"Clin Interv Aging."},{"issue":"4","key":"pone.0309902.ref015","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.MGM2-0023-2013","article-title":"Mechanisms of Pyrazinamide Action and Resistance.","volume":"2","author":"Y Zhang","year":"2014","journal-title":"Microbiol Spectr."},{"issue":"18","key":"pone.0309902.ref016","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.2169\/internalmedicine.54.5533","article-title":"Currently Used Low-Dose Pyrazinamide Does Not Increase Liver-Injury in the First Two Months of Tuberculosis Treatment","volume":"54","author":"N Horita","year":"2015","journal-title":"Intern Med"},{"issue":"3","key":"pone.0309902.ref017","first-page":"297","article-title":"[Comparison of drug-induced hepatitis occurring in elderly and younger patients during anti-tuberculosis treatment with a regimen including pyrazinamide].","volume":"88","author":"N Miyazawa","year":"2013","journal-title":"Kekkaku."},{"issue":"12","key":"pone.0309902.ref018","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jiac.2019.05.030","article-title":"Safety of pyrazinamide-including regimen in late elderly patients with pulmonary tuberculosis: A prospective randomized open-label study","volume":"25","author":"E Hagiwara","year":"2019","journal-title":"J Infect Chemother"},{"issue":"10","key":"pone.0309902.ref019","doi-asserted-by":"crossref","first-page":"e021235","DOI":"10.1136\/bmjopen-2017-021235","article-title":"Cohort Study of Pulmonary Tuberculosis (COSMOTB) identifying drug-resistant mutations: protocol for a prospective observational study in Korea.","volume":"8","author":"J Min","year":"2018","journal-title":"BMJ Open."},{"key":"pone.0309902.ref020","article-title":"Tuberculosis notification and incidence\u2014Republic of Korea, 2022.","author":"J Min","year":"2024","journal-title":"Tuberc Respir Dis (Seoul)."},{"key":"pone.0309902.ref021","article-title":"Annual report on the notified tuberculosis patients in Korea 2023.","author":"KDCA","year":"2023","journal-title":"Cheongwon: Korea Disease Control and Prevention Agency"},{"issue":"2","key":"pone.0309902.ref022","doi-asserted-by":"crossref","first-page":"160","DOI":"10.5588\/ijtld.13.0369","article-title":"Reasons for defaulting from drug-resistant tuberculosis treatment in Armenia: a quantitative and qualitative study","volume":"18","author":"E Sanchez-Padilla","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"issue":"8","key":"pone.0309902.ref023","doi-asserted-by":"crossref","first-page":"ofad422","DOI":"10.1093\/ofid\/ofad422","article-title":"Metabolic Disorders Are Associated With Drug-Induced Liver Injury During Antituberculosis Treatment: A Multicenter Prospective Observational Cohort Study in Korea.","volume":"10","author":"J Lim","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"pone.0309902.ref024","first-page":"1367","article-title":"Results of cohort analysis by category of tuberculosis retreatment cases in Morocco from 1996 to 2003.","volume":"10","author":"SE Ottmani","year":"2006","journal-title":"Int J Tuberc Lung Dis."},{"issue":"5","key":"pone.0309902.ref025","doi-asserted-by":"crossref","first-page":"652","DOI":"10.5588\/ijtld.10.0400","article-title":"Multidrug-resistant tuberculosis among previously treated patients in the Philippines","volume":"15","author":"MT Gler","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"pone.0309902.ref026","first-page":"81","article-title":"Excess mortality and risk factors for mortality among a cohort of TB patients from rural south India","volume":"12","author":"C Kolappan","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"issue":"4","key":"pone.0309902.ref027","doi-asserted-by":"crossref","first-page":"e93574","DOI":"10.1371\/journal.pone.0093574","article-title":"Treatment default amongst patients with tuberculosis in urban Morocco: predicting and explaining default and post-default sputum smear and drug susceptibility results","volume":"9","author":"I Cherkaoui","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"pone.0309902.ref028","doi-asserted-by":"crossref","first-page":"5631","DOI":"10.1038\/s41598-024-55273-5","article-title":"The prevalence, clinical reasoning and impact of non-standard anti-tuberculosis regimens at the initial prescription.","volume":"14","author":"RT Chen","year":"2024","journal-title":"Sci Rep."},{"issue":"12","key":"pone.0309902.ref029","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1164\/rccm.200802-355OC","article-title":"Hepatotoxicity of pyrazinamide: cohort and case-control analyses","volume":"177","author":"KC Chang","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"pone.0309902.ref030","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40495-018-0131-8","article-title":"Genetic Variations Associated with Anti-Tuberculosis Drug-Induced Liver Injury.","volume":"4","author":"Y Bao","year":"2018","journal-title":"Curr Pharmacol Rep"},{"issue":"1","key":"pone.0309902.ref031","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s12879-019-4010-7","article-title":"Impact of renal function-based anti-tuberculosis drug dosage adjustment on efficacy and safety outcomes in pulmonary tuberculosis complicated with chronic kidney disease","volume":"19","author":"N Saito","year":"2019","journal-title":"BMC Infect Dis"},{"issue":"6","key":"pone.0309902.ref032","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.jiph.2023.04.009","article-title":"Anemia and anti-tuberculosis treatment outcome in persons with pulmonary tuberculosis: A multi-center prospective cohort study","volume":"16","author":"M Ara\u00fajo-Pereira","year":"2023","journal-title":"J Infect Public Health"},{"issue":"9","key":"pone.0309902.ref033","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.3346\/jkms.2014.29.9.1226","article-title":"Risk factors for death during pulmonary tuberculosis treatment in Korea: a multicenter retrospective cohort study","volume":"29","author":"YS Kwon","year":"2014","journal-title":"J Korean Med Sci"},{"issue":"12","key":"pone.0309902.ref034","first-page":"1441","article-title":"Predicting tuberculosis treatment outcome in a low-incidence area","volume":"12","author":"I Baussano","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"pone.0309902.ref035","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/1471-2458-7-291","article-title":"Risk factors for poor tuberculosis treatment outcome in Finland: a cohort study","volume":"7","author":"T Vasankari","year":"2007","journal-title":"BMC Public Health"},{"issue":"5","key":"pone.0309902.ref036","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/thx.46.5.347","article-title":"Deaths in adults with notified pulmonary tuberculosis 1983\u20135.","volume":"46","author":"P Cullinan","year":"1991","journal-title":"Thorax"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0309902","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T14:34:10Z","timestamp":1732804450000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0309902"}},"subtitle":[],"editor":[{"given":"Lisa","family":"Kawatsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,9,26]]},"references-count":36,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0309902","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,26]]}}}